X

Trial Profile

The effect of Riluzole on negative symptoms in patients with chronic schizophrenia: a double blind and placebo controlled trial.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 18 Sep 2015

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Riluzole (Primary) ; Risperidone
Indications Schizophrenia
Focus Therapeutic Use

Most Recent Events

18 Sep 2015 Status changed from active, no longer recruiting to completed.
04 Jul 2012 Planned end date changed from 23 Sep 2013 to 23 Jun 2012 as reported by Iranian Registry of Clinical Trials.
04 Jul 2012 Status changed from recruiting to active, no longer recruiting as reported by Iranian Registry of Clinical Trials.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com